What’s going on here? Tech giants like Nvidia and Tesla helped nudge the Nasdaq up 0.1% on Friday, even as fresh inflation data quashed optimism for a December Federal Reserve rate cut. After a wobbly ...

Cost cuts and strategic asset moves helped Modiv Industrial top profit forecasts, keeping analysts bullish despite its high price tag. For markets: Defying valuation worries with growth and conviction ...

Join the newsletter that everyone in finance secretly reads. 1M+ subscribers, 100% free. The specialty drugmaker is offering 4.67 million shares in the US at $7.50 apiece, also handing underwriters an ...

Investors are counting on Nvidia’s update to set the tone for tech and AI stocks, as concerns about valuations and market swings linger. All eyes are on Nvidia’s latest earnings as investors wonder if ...

S&P 500 crept up as health care stocks outperformed, but stalled economic data leaves investors and the Fed waiting for more direction. The S&P 500 barely squeezed out a 0.1% gain this week, powered ...

Diverging views at the Fed highlight uncertainty on when to ease policy, with some officials pushing for patience and others warning rates may already be too restrictive. Federal Reserve officials are ...

A rebounding dollar, UK political twists, and delayed US economic reports are keeping investors guessing on rate cuts and volatility. Currency and equity markets are in a holding pattern, as traders ...

Nvidia and Microsoft climbed on upbeat outlooks while rate cut hopes faded, giving tech a leg up even as other sectors fell behind. Tech stocks kept defying gravity on Wall Street, with the Nasdaq ...

Strong gains in energy shares followed higher oil prices, fresh supply contracts, and upbeat outlooks from majors like Exxon Mobil and Chevron. Energy shares are back in focus: the NYSE Energy Sector ...

The TSX climbed to new highs with energy and technology shares leading gains, while investors weighed rising oil prices and mixed signals from Wall Street. The S&P/TSX composite index gained 1.4% for ...

Despite a steep quarterly loss, analysts unanimously recommend buying Eledon Pharmaceuticals as it secures new funding to drive its transplantation research forward. Eledon Pharmaceuticals posted a ...

After revenue dipped and losses held steady, the company is banking on its AVO collegiate brand and a new creative direction to turn things around. Challenging wholesale conditions kept Digital Brands ...